The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options, Issue of Shares, Director/PDMR

3 Jul 2023 07:00

RNS Number : 6560E
NetScientific PLC
03 July 2023
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Grant of Options, Issue of Shares, Director/PDMR Shareholding and Total Voting Rights

 

 

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that it has granted a total of 579,703 new options (New Options) to subscribe for ordinary shares in the capital of the Company (Ordinary Shares) to certain of its directors, as detailed below. In addition, certain of its directors have subscribed for and purchased shares in the Company, as detailed below.

 

Grant of new options

In line with the Company's remuneration policy, the Remuneration Committee has approved the award of the following New Options to the directors referred to below in connection with their recent appointments and roles:

Director

New Options

Total options held (including existing options)

Ed Hooper, Executive Director

460,656

565,656

Dr Charles Spicer, Chair

95,238

95,238

Dr Jonathan Robinson, Senior Independent Director

23,809

69,610

 

The New Options were granted under the NetScientific Share Option Scheme, pursuant to which options over a total of 2,310,095 Ordinary Shares have now been granted (excluding lapsed options but including exercised options), representing approximately 9.82 per cent. of the Enlarged Issued Share Capital (as defined below). The maximum potential dilution arising from options awarded under the NetScientific Share Option Scheme remains below the upper limit of 10 per cent. under the rules of the plan.

 

The New Options have an exercise price of 63 pence per share, which is equal to the average of the closing market quotations for Ordinary Shares over the five dealing days prior to the date on which the New Options were granted (the latter being the minimum price that could have been set).

 

The New Options will vest as to one third on the date of grant, as to a further third on the first anniversary of the date of grant and as to the final third on the second anniversary of the date of grant. The New Options may not be exercised earlier than the third anniversary of the date of grant and lapse 10 years after the date of grant (if not sooner in accordance with the terms of the NetScientific Share Option Scheme rules).

 

The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation, is appended below.

 

Issue of new Ordinary Shares

 

Ed Hooper has chosen to receive payment in the form of 40,000 new Ordinary Shares (New Shares), rather than cash, in respect of c.77.5 per cent. of the annual bonus awarded to him (on a projected net of tax basis) for the year ended 31 December 2023. The new Ordinary Shares are being issued at a price of £0.63 per share, being determined on the same basis as described above in respect of the New Options.

 

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 7 July 2023 (Admission). The New Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Purchase of Ordinary Shares

 

On 30 June 2023 the following directors purchased shares in the Company through their Self Invested Personal Pensions, as detailed below (Director Dealings).

 

Director

Number of Ordinary Shares acquired

Total number of Ordinary Shares in which interested

% of Enlarged Issued Share Capital

Ed Hooper, Executive Director

20,000

60,000

0.26

Dr Charles Spicer, Chair

16,286

16,286

0.07

 

Total Voting Rights 

 

Upon Admission, the issued share capital of the Company will consist of 23,528,148 Ordinary Shares (Enlarged Issued Share Capital). The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company from Admission will be 23,528,148. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail on the grant of options to PDMRs, the issue of the New Shares and the Director Dealings.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

460,656 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Charles Spicer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

95,238 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Jonathan Robinson

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

23,809 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Subscription for new Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

40,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.5962

20,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Charles Spicer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.614

16,286 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

 

# # #

 

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel / Enzo Aliaj

+44 (0)20 7220 1666

Belvedere Communications

John West / Llew Angus

 

+44 (0)20 3008 6867

 

About NetScientific

NetScientific plc (AIM: NSCI) is deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDRBBGDGXD
Date   Source Headline
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data
3rd Nov 20164:34 pmRNSVortex Gains CE Mark and FDA Class 1 Registration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.